# Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

> **NCT00676663** · PHASE2 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Breast Cancer
- Estrogen Receptor-Positive Breast Cancer
- Breast Cancer, Estrogen Receptor-Positive
- ER+ Breast Cancer

## Interventions

- **DRUG:** entinostat
- **DRUG:** exemestane
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00676663
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-13
- **Primary completion:** 2011-01-29
- **Final completion:** 2012-11-26
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676663, "Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00676663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*